Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)

University Hospital, Clermont-Ferrand151 enrolled

Overview

The primary purpose of the study is to evaluate whether dexmedetomidine is effective in treating agitated delirium of non-intubated ICI patients

Delirium during intensive care unit (ICU) stay is frequent and associated with significant morbidity, mortality and healthcare related costs. International guidelines suggest its prevention. However, curative treatment remains unclearly established. Despite a non-unequivocal literature, haloperidol is the first line recommended neuroleptic. Dexmedetomidine, an alpha2-adrenergic receptors agonist has shown its efficiency in the treatment of delirium in intubated patients but also in its prevention. Dexmedetomidine represents a widely used alternative to haloperidol. Only few studies have compared the efficacy of dexmedetomidine in non-intubated ICU patients as a first line curative treatment of delirium. Main objective of 4D trial is to demonstrate that dexmedetomidine decreases delirium duration compared to placebo. The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure. The primary outcome measure is a composite of duration of agitation or delirium or the use of intubation with deep sedation and mechanical ventilation. Secondary outcomes include mortalities at 7 and 28 days, ICU length of stay and occurrence of adverse effects. The sample size will allow the detection of a 50% decrease of agitation duration (120 minutes), of an absolute reduction of delirium duration (1 day) and of a 50% relative decrease of intubation and mechanical ventilation, with a type 1 error rate of 1.8 % (error risk inflation due to components of composite) and power of 90 %, assuming a 15 % incidence of intubation and mechanical ventilation requirements, an agitation duration of 240 minutes and a delirium duration of 3 days. One hundred and 10 patients by group will be needed. A intermediate analysis is scheduled and requires the inclusion of 150 patients in each group. The 4D trial may provide important data on the safety of commonly used sedative dexmedetomidine and could have a significant impact on future treatment of non-intubated ICU patients presenting with agitated delirium.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

151

Conditions

Delirium Agitation

Interventions

DexmedetomidineDRUG

The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure

PlaceboOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * • Age \> 18 years * Patient hospitalized in an ICU * Presenting a productive delirium according to the following criteria: * acute onset (\<2h) and fluctuating course during the same day * alteration of cognitive functions: disorganization of thought (delirium of persecution, inability to reason logically), abnormal perceptions (hallucinations), memory impairments, temporal disorientation, non- or misrecognitions, difficulties in naming objects or writing) * in whom a simple cropping and non-medicated therapeutics are not sufficient to allow symptoms' resolution for few hours * CAM-ICU positive AND a RASS \> +1 * Non-intubated or extubated (\> 24h) * No contraindication of dexmedetomidine or haloperidol uses Exclusion Criteria: * • Age \<18 years * Administration of dexmedetomidine and/or clonidine during the 72 hours before inclusion * Contraindication to the use of Dexmedetomidine, clonidine or haloperidol (history of allergy, Parkinson's disease, oro-pharyngeal dysfunction, arterial hypotension or bradycardia, QTc interval prolongation, and hepatic or renal dysfunction), as mentioned in the Summaries of Product Characteristics * Neuropsychiatric pathology judged by the investigator as a potential source of bias (in particular: active drug addiction, psychosis...) * Parturient or breast-feeding woman * Protected major (guardianship) * Patient's or relative's refusal to participate

Locations (1)

CHU Clermont-Ferrand

Clermont-Ferrand, France

Outcomes

Primary Outcomes

duration of agitation (in hours), defined by a RASS ≥ +1

Time frame: at day 1

duration of delirium (in days), defined by a positive CAM-ICU

Time frame: at day 1

delay (in hours) between inclusion and intubation requirement to control delirium with deep sedation and mechanical ventilation

requirement of intubation to control delirium with deep sedation and mechanical ventilation

Time frame: at day 1

Secondary Outcomes

Length of ICU stay (in days)

Time frame: at day 1

Number of ventilator free days

Time frame: at day 30

Adverse effects such as the occurence of pneumonia (following the ATS definitions) and/or septicemia

Time frame: at day 30

Duration of mechanical restraint prescribed and carried out

Time frame: at day 30

Occurrence of tachycardia

Time frame: at day 30

Occurrence of hypotension requiring any vasopressor administration

Time frame: at day 30

All-cause mortality

Time frame: at day 30

All-cause mortality

Time frame: at day 7

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.